UMB Bank n.a. lessened its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 5.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 581,700 shares of the biopharmaceutical company’s stock after selling 33,490 shares during the quarter. UMB Bank n.a.’s holdings in Pfizer were worth $29,807,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in PFE. Karp Capital Management Corp purchased a new position in Pfizer in the 3rd quarter worth $27,000. Worth Asset Management LLC purchased a new position in shares of Pfizer in the first quarter valued at about $29,000. Delos Wealth Advisors LLC increased its position in shares of Pfizer by 100.0% in the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 400 shares during the period. Legend Financial Advisors Inc. purchased a new position in shares of Pfizer in the third quarter valued at about $42,000. Finally, Align Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter valued at about $45,000. Hedge funds and other institutional investors own 67.62% of the company’s stock.
Pfizer Trading Down 0.7 %
NYSE:PFE opened at $40.10 on Friday. Pfizer Inc. has a one year low of $39.23 and a one year high of $56.32. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00. The company’s 50-day simple moving average is $43.26 and its 200 day simple moving average is $46.03. The firm has a market capitalization of $225.33 billion, a P/E ratio of 7.32, a PEG ratio of 1.33 and a beta of 0.64.
Analysts Set New Price Targets
PFE has been the topic of a number of analyst reports. Barclays decreased their price objective on shares of Pfizer from $49.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 1st. JPMorgan Chase & Co. set a $45.00 price objective on shares of Pfizer in a research report on Monday, February 27th. SVB Leerink decreased their price objective on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 1st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price objective on the stock in a research report on Tuesday, February 7th. Finally, Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 target price on the stock. in a research note on Wednesday, January 4th. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $50.38.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.